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Introduction 
Amyopathic dermatomyositis (ADM) is a variant of 
dermatomyositis (DM) and occurs in approximately 
20% of cases [1]. Amyopathic dermatomyositis is an 
autoimmune process that presents with typical 
cutaneous signs (Gottron papules, heliotrope rash) 
and symptoms (pruritus, fatigue), but lacks the 
pathognomonic proximal muscle weakness of 
typical DM [2]. Treatments range from topical 
corticosteroids to oral immunosuppressants and 
immunomodulators. These treatments, however, 
come with many adverse side effects and are not 
uniformly effective [3]. Recently, several case reports 
have demonstrated the efficacy of low-dose 
naltrexone in multiple autoimmune, dermatologic 
conditions (Hailey-Hailey disease, alopecia areata, 
lichen planopilaris) including dermatomyositis. 
Herein we report the use and efficacy of low-dose 
naltrexone in the treatment of ADM in one patient [4-7]. 
 
Case Synopsis 
A 56-year-old man presented with Gottron papules, 
a heliotrope rash, periungual changes, holster sign, 
scalp erythema, and generalized pruritus. Past 
medical and social histories were non-contributory. 
Pertinent negatives included the absence of 
clinically significant proximal muscle weakness and 
pain. A punch biopsy of lesional forearm skin was 
performed and treatment was initiated with 
clobetasol shampoo for the scalp and 
hydrocortisone 2.5% ointment for other affected 
areas. 
Two weeks after initial evaluation, there was no 
noticeable improvement in his condition. Blood tests 
showed positive (1:640) speckled pattern ANA and 
elevated lactate dehydrogenase (LDH), (258 IU/L, 
normal range 121-224 IU/L). Creatine kinase and 
aldolase were within normal limits. An extractable 
nuclear antigen assay was negative for all 
components — SSA, SSB Sm, nRNP, Scl-70, and Jo-1. 
Laboratory evaluation for anti-MDA5, anti-TIF1γ, and 
anti-NXP2 antibodies was not performed owing to 
high cost and lack of local availability. The skin 
biopsy demonstrated interface dermatitis and mucin 
Abstract 
Gottron papules, a heliotrope rash, scalp and 
extremity erythema, pruritus, and fatigue are the 
characteristic signs and symptoms of amyopathic 
dermatomyositis (ADM). Amyopathic dermatomyositis 
is considered a distinct entity from dermatomyositis 
(DM) because the characteristic muscle weakness 
and muscle enzyme elevations of DM are absent in 
ADM. With respects to treatment, ADM treatments 
have traditionally included topical corticosteroids 
and/or systemic immunosuppressants and immune-
modulators. Herein we present a patient with 
refractory ADM that was responsive to low-dose 
naltrexone therapy. 
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deposition highly suggestive of connective tissue 
disease (Figure 1). Given current diagnostic 
recommendations, a clinical diagnosis of ADM was 
made based on the clinical picture and the 
corresponding laboratory and pathologic findings. 
The differential diagnosis included lichenoid drug 
eruption or photoeruption, but were less likely given 
the clinical presentation and lack of offending 
medications. Lung cancer screening completed via 
chest X-ray was deemed negative. Topicaltreatment 
was discontinued and prednisone 50mg by mouth 
was initiated. 
Symptoms improved initially; however, flaring 
occurred with steroid tapering. Therefore, at his two-
month follow up, the patient was started on oral 
hydroxychloroquine 200mg daily and prednisone 
was discontinued. Hydroxychloroquine was started 
at a lower dose because the patient was an 
optometrist and was nervous about visual side 
effects. Weekly methotrexate, 20mg 
subcutaneously, was then added to the treatment 
regimen four weeks later in an effort to enhance and 
hasten therapeutic success. During this time, the 
lesions became more prominent and symptoms 
worsened. Increased severity of symptoms despite 
treatment with hydroxychloroquine and 
methotrexate prompted the search for additional 
treatment options. 
Our patient eventually brought to our attention low-
dose naltrexone as a potential therapeutic option. He 
had learned of low-dose naltrexone through reports 
of its use in other autoimmune, dermatologic 
disorders [4-6]. Notably, there have been two cases 
reported of successful DM treatment with low-dose 
naltrexone [7]. Because of his finding and his interest 
in adding it to his therapeutic regimen, low-dose 
naltrexone was added. 
The patient was started on 1.5mg/day of low-dose 
naltrexone and methotrexate was stopped. Within a 
month, the scalp pruritus and burning sensation 
resolved and facial erythema became less apparent. 
The low-dose naltrexone dose was gradually titrated 
to 4.5mg/day and hydroxychloroquine was stopped. 
Lesions on his elbows, hands, and knees continued 
to improve in the months thereafter. At this time, the 
patient is maintained on 4.5mg of daily low-dose 
naltrexone and now has mild erythema of the hands 
and knuckles that continues to improve. Figure 2 
demonstrates our patient’s response to therapy. 
 
Case Discussion 
Amyopathic dermatomyositis is an uncommon 
variant of DM that occurs in approximately 20% of 
DM cases [1]. Dermatomyositis and ADM are 
connective tissue diseases that classically present 
with Gottron papules, shawl sign, facial erythema, 
periorbital swelling, periungual telangiectasias, 
photosensitivity, arthralgia, and Raynaud 
phenomenon [2]. Amyopathic dermatomyositis, 
 
 
Figure 1.  Amyopathic dermatomyositis. Sections from a punch 
biopsy specimen show A) subacute interface dermatitis with 
squamotization of the epidermal basal layer, intrabasal 
lymphocytes and occasional necrotic keratinocytes. (H&E; 20×) B) 
There is a marked increase in reticular dermal mucin. (H&E; 20×). 
B 
A 
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however, lacks the clinically relevant muscle 
involvement and weakness of traditional DM. If 
muscle involvement develops, it typically will 
happen within the first decade after diagnosis and is 
identified because of symptom presentation and/or 
elevated muscle enzymes. Amyopathic 
dermatomyositis may be idiopathic but may also be 
a sign of an underlying malignancy. A Swedish study 
based on population data determined that DM has 
an associated malignancy rate of 15% [1]. In addition 
to malignancy, DM has also been associated with 
pulmonary fibrosis [2]. 
Insight into disease pathogenesis remains elusive; 
however, certain disease markers have been 
identified. The proteins Jo-1, Mi-2, and TIF1 may be 
elevated and are associated with developing 
autoimmunity following environmental triggers. 
Specific autoantibodies are also associated with 
ADM: anti-CADM-140 and anti-p155. Anti-CADM-140 
inhibits MDA5 RNA helicase, a protein offering 
protection against viral infection, implicating a link 
between viral infection and ADM. The autoantibody 
anti-p155 inhibits TIF1 and has been detected in up 
to 58% of individuals with ADM and concurrent 
cancer [8]. The gold standard to detect these 
antibodies is an immunoprecipitation assay; 
however, it can be cost-prohibitive and not suitable 
for routine use in a clinical setting [9]. 
Once diagnosed, ADM treatment is variable. Topical 
therapies can be used for cutaneous lesions, but a 
systemic approach with corticosteroids, 
methotrexate, cyclosporine, azathioprine, rituximab, 
and/or hydroxychloroquine is often required [3]. Two 
cases of DM treated with low-dose naltrexone have 
been reported in the literature [7]. Likewise, the 
efficacy of low-dose naltrexone has been reported in 
other autoimmune, dermatologic diseases (alopecia 
areata, Hailey-Hailey disease, and lichen 
planopilaris), [4-6]. Traditionally, low-dose 
naltrexone dosing ranges from 1-4.5mg/day, 
whereas standard naltrexone dosing ranges from 50-
100mg/day and is used for the treatment of opioid 
and alcohol dependency, initial FDA indications for 
naltrexone [4]. 
Mechanistic insight into the efficacy of low-dose 
naltrexone is still limited, but a few mechanisms have 
been proposed. low-dose naltrexone administration 
increases beta endorphin (BE) levels and high levels 
of BE are associated with lower erythrocyte 
sedimentation rates, implying a reduced systemic 
inflammatory state [10]. low-dose naltrexone may 
also work through its blockade of toll-like receptor 4 
(TLR4). When blocked, TLR4 cannot stimulate the 
release of inflammatory cytokines and other 
mediators (substance P, nitric oxide, and excitatory 
amino acids) by astrocytes, macrophages, and 
microglia [11]. This lack of TLR4-mediated cytokine 
and mediator release results in anti-inflammatory 
effects [12]. 
The importance of this case lies in its support for the 
treatment efficacy of low-dose naltrexone in 
autoimmune dermatologic disease. Seeing efficacy 
in more than one disease state, whether 
dermatologic or not, adds validity to the idea that 
low-dose naltrexone is actually having an effect and 
that the recent reports are not simply a coincidence. 
Additionally, low-dose naltrexone adds a possible 
low-cost, limited-side-effect treatment option for our 
patients, which should be considered. Further 
research is clearly required to understand why low-
dose naltrexone may be effective; however, the rarity 
of many autoimmune, dermatologic diseases creates 
a major challenge for researchers. 
 
Conclusion 
Patients with amyopathic dermatomyositis require 
treatment for their debilitating signs and symptoms, 
but current treatments have many adverse side 
effects, which make them inadvisable or undesirable  
Figure 2. Amyopathic Dermatomyositis. A) Gottron’s papules 
observed before LDN administration and B) after 8 months of 
treatment showing improvement. 
A B 
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to patients and practitioners. Low-dose naltrexone 
has emerged as an alternative treatment option for 
patients owing to its efficacy and limited toxicity as 
seen in the treatment of several autoimmune 
dermatologic conditions including our case of ADM 
[4-7]. The evidence for safety and efficacy, however, 
is still limited and further evaluation through well-
designed research is required. Before starting a 
patient on low-dose naltrexone, a robust discussion 
of risks and benefits between patient and provider 
should be performed. 
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